German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies

Haemophilia

Volumn 5, Issue 3, 1999, Pages 203-206

  Brackmann, H H ^a,e   Lenk, H ^b   Scharrer, I ^c   Auerswald, G ^d   Kreuz, W ^c  

^a Inst Exp Haematol/Transfus Med   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d Central Hospital   (Germany)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

Haemophilia A; High responder; Immune tolerance treatment; Inhibitor; Low responder

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; CORTICOSTEROID; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIBODY TITER; ARTICLE; BLEEDING; DRUG CROSS REACTIVITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG TOLERANCE; DRUG WITHDRAWAL; GERMANY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; INTRAVENOUS DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; VEIN CATHETERIZATION;

ANTIBODIES; FACTOR VIII; GERMANY; GUIDELINES; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; RECOMBINANT PROTEINS;

EID: 0032787814     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00311.x     Document Type: Article

References (16)

1. Federal Chamber of Physicians. Konsensus Empfehlungen zur Hämophiliebehandlung in Deutschland. Haemostaseologie 1994; 14: 81-3.
2. Federal Chamber of Physicians. Leitfaden zur Therapie mit Blutkomponenten und Plasmaderivaten. Germany: Ärzte-Verlag. 1995.
3. Brackmann H-H, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years 'bonn protocol'. Vox Sang 1996; 70: 30-5.
4. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
5. Ewing N, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to Factor VIII in hemophiliacs. JAMA 1988; 259: 65-8.
6. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia. Principal results from the international registry. Thromb Haemost 1994; 72: 155-8.
7. DiMichele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) (1993-1997): Current practice implications. Blood 1997; 90 (Suppl. 1): 156a.
8. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of Factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
9. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability. Thrombosis and Haemostasis. Stuttgart: Schattauer Verlagsgesellschaft, 1995; 73(2): 247-51.
10. Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. New Engl J Med 1981; 305: 717-21.
11. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with Factor VIII and Factor IX inhibitors. Thromb Haemost 1997; 77: 1113-19.
12. Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in patients with severe haemophilia A during synovectomy. Lancet 1988; ii: 1193.
13. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (Novo Seven) in haemophilia patients with inhibitos undergoing surgery. Thromb Haemost 1998; 80: 773-8.
14. Brettler DB, Forsberg MS, Levine PH, et al. on behalf of the Cooperating Investigors. The use of porcine Factor VIII concentrate (Hyate: C) in the treatment of patients with inhibitor antibodies to factor VIII. A Multicenter US Experience. Arch Intern Med 1989; 149: 1381-5.
15. Hay CRM, Lozier JN, Lee CA, Tradati H, Santagostino E, Ciavarella N, Schiavoni M, Fukiu H, Yoskioka A. Porcine factor VIII in patients with congenital hemophilia and inhibitors: efficacay, patient selection and side effects. Semin Hematol 1994; 31: 20-5.
16. Kreuz W, Ehrenforth M, Furk G, Auerswald D, Meutzer J, Joseph-Steiner T, Berg D, Kearmann J, Scharrer S, Kornhuber B. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.